4.47
+1.13%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About LeonaBio
From its filings with the US Securities and Exchange Commission
LeonaBio is based in Bothell, Washington. Its shares trade on Nasdaq under the ticker LONA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $105.6m. At that date it held total assets of $92.2m and shareholders' equity of $27.8m.
We are a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (“ALS”), with the goal of improving patients’ lives.
Following a review of potential therapeutic and business opportunities, we acquired rights to a promising late-stage asset, lasofoxifene, for the potential treatment of ESR1-mutated (“mESR1”) metastatic breast cancer in December 2025. This late-stage program has generated promising clinical data and we believe it represents a unique and exciting opportunity to diversify our pipeline. We believe this program fits well with our later-stage clinical development experience, and complements our in-house asset, ATH-1105, a Phase-2 ready program for the potential treatment of ALS.
The drug development landscape in both oncology and neuroscience is evolving rapidly, driven by breakthroughs in genetics, disease biology, and molecular pathway research. We are leveraging this scientific momentum to advance a pipeline of innovative, late-stage assets both internally developed and strategically in-licensed with the goal of accelerating their path to market and maximizing their clinical and commercial impact.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Sept 2020
- Employees
- 20
- Website
- athira.com ↗
- Head office
- 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Kelly RomanoIndependent Chairwoman of the Board$90,657
- Dr. Mark LittonPresident, Chief Executive Officer, Director, since 2019$1.4m
- Mr. Robert RenningerChief Financial Officer
- Dr. Kevin ChurchChief Scientific Officer, since 2023$1.3m
- Mr. Mark WorthingtonChief Compliance Officer, General Counsel, Company Secretary$731,477
- Dr. Javier San MartinChief Medical Officer$810,135
- Mr. Joseph EdelmanIndependent Director$49,157
- Mr. John FlukeIndependent Director$52,657
- Mr. James JohnsonIndependent Director$70,157
- Ms. Barbara KosaczIndependent Director$59,157
- Dr. Michael PanzaraIndependent Director$59,157
- Mr. Grant PickeringIndependent Director$50,157
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 43
- Environment
- 47
- Social
- 42
- Governance
- 41
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- LeonaBio Inc has a clinical-stage biopharmaceutical focus on small molecules targeting neurodegeneration.
- The ATH platform utilizes proprietary technology for neuronal growth factor enhancement.
- Athira Pharma's pipeline includes ATH-1017 for Alzheimer's disease treatment.
Weaknesses
- LeonaBio Inc employs only 20 full-time employees in Bothell, Washington.
- The company's IPO occurred in 2020 with limited financial resources.
- Athira Pharma's clinical-stage development faces regulatory hurdles in the US.
Opportunities
- The growing Alzheimer's disease market in the US presents significant opportunities.
- LeonaBio Inc can expand its ATH platform to target peripheral nervous system disorders.
- The US healthcare sector's increasing focus on neurodegenerative treatments offers growth potential.
Threats
- The US pharmaceutical industry faces intense competition from established biotech firms.
- Regulatory challenges in drug approval processes could delay ATH-1017 development.
- The US market's high R&D costs for neurodegenerative drugs pose financial risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.